Sernova Biotherapeutics Inc
SVA.TO
TSX
| 07/31/2025 | 04/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.42% | -11.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.32% | -9.88% | |||
| Operating Income | 16.32% | 9.88% | |||
| Income Before Tax | -12.09% | 34.26% | |||
| Income Tax Expenses | -40.54% | 475.56% | |||
| Earnings from Continuing Operations | -11.57% | 33.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.57% | 33.69% | |||
| EBIT | 16.32% | 9.88% | |||
| EBITDA | 17.91% | 9.98% | |||
| EPS Basic | -11.11% | 33.61% | |||
| Normalized Basic EPS | -14.00% | 34.21% | |||
| EPS Diluted | -11.11% | 33.61% | |||
| Normalized Diluted EPS | -14.00% | 34.21% | |||
| Average Basic Shares Outstanding | 0.00% | 0.31% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||